natgillin/translations-raw huggingface dataset:
Det er nødvendigt at MR-skanne patienten for at stille PRES-diagnosen.
Magnetic resonance imaging is necessary to confirm the diagnosis of PRES.
Skema 1.
Figure 1.
Samtidig administration af axitinib og potente CYP3A4/5-induktorer (f.eks. rifampicin, dexamethason, phenytoin, carbamazepin, rifabutin, rifapentin, phenobarbital og perikon) kan nedsætte plasmakoncentrationen af axitinib.
Co-administration of axitinib with strong CYP3A4/5 inducers (e.g. rifampicin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentin, phenobarbital, and Hypericum perforatum [St.
Spørg lægen, på apotekespersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om.
You should check with your doctor, pharmacist or nurse if you are not sure.
Figur 3 Kaplan-Meier kurve over progressionsfri overlevelse udfra uafhængig vurdering i undergruppen med tidligere cytokin-behandling.
Kaplan-Meier curve of progression-free survival by independent assessment for the prior cytokine subgroup
Dosisjustering er ikke nødvendig hos patienter med let nedsat leverfunktion (Child-Pugh klasse A).
No dose adjustment is required when administering axitinib to patients with mild hepatic impairment (Child-Pugh class A).
Hvis behandlingen med axitinib afbrydes, bør blodtrykket kontrolleres med henblik på hypotension hos patienter i antihypertensiv behandling (se pkt.
If axitinib is interrupted, patients receiving antihypertensive medicinal products should be monitored for hypotension (see section 4.2).
I kliniske studier med axitinib til behandling af patienter med RCC, blev hypertension meget hyppigt rapporteret (se pkt.
In clinical studies with axitinib for the treatment of patients with RCC, hypertension was very commonly reported (see section 4.8).
In vitro studier antyder, at axitinib er en potentiel hæmmer af CYP2C8.
In vitro studies also indicated that axitinib has the potential to inhibit CYP2C8.
Axitinib er en potent og selektiv hæmmer af VEGF (Vascular Endothelial Growth Factor).
Axitinib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2 and VEGFR-3.
• Fald i antal blodplader (der gør at blodet har sværere ved at størkne) (ses i blodprøver)
• Reduction in the number of blood platelets (cells that help blood to clot) (may show in your blood tests)
Kontakt omgående læge eller skadestue, ved symptomer som smerter eller trykken for brystet, smerter i armene, ryggen, nakken eller kæben, åndenød, følelsesløshed eller svaghed i den ene side af kroppen, problemer med at tale, hovedpine, synsforstyrrelser eller svimmelhed, mens du bliver behandlet med dette lægemiddel.
Get emergency help right away and call your doctor if you get symptoms such as chest pain or pressure; pain in your arms, back, neck or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; headache; vision changes; or dizziness while on treatment with this medicine.
DATO FOR FØRSTE MARKEDSFØRINGSTILLADELSE/FORNYELSE AF TILLADELSEN
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 3 September 2012
Hvis skjoldbruskkirtlen ikke producerer nok hormon, kan der gives et medicinsk tilskud af skjoldbruskkirtelhormon.
If your thyroid gland is not producing enough thyroid hormone before, or while on treatment with this medicine, you should be treated with thyroid hormone replacement.
Der sås ingen virkning på parringsevne og fertilitet hos hanmus ved doser ca. 57 gange human-terapeutiske doser.
There was no effect on mating or fertility in male mice at exposure levels approximately 57-fold the expected human exposure.
Skjoldbruskkirtlens funktion skal måles, inden du begynder at tage Inlyta og regelmæssigt under behandlingen.
Your thyroid function should be checked before you take Inlyta and regularly while you are taking it.
Fortæl det til lægen, hvis du oplever usædvanlig træthed, opsvulmet mave, hævede ben eller ankler, åndenød eller fremstående blodårer på halsen.
Tell your doctor if you experience excessive tiredness, swelling of the abdomen, legs, or ankles, shortness of breath, or protruding neck veins.
In vitro studier antyder, at axitinib er en potentiel hæmmer af CYP1A2.
In vitro studies indicated that axitinib has a potential to inhibit CYP1A2.
Inlyta 1 mg filmovertrukne tabletter Inlyta 3 mg filmovertrukne tabletter Inlyta 5 mg filmovertrukne tabletter Inlyta 7 mg filmovertrukne tabletter axitinib
Inlyta 1 mg film-coated tablets Inlyta 3 mg film-coated tablets Inlyta 5 mg film-coated tablets Inlyta 7 mg film-coated tablets axitinib
I kliniske studier med axitinib til behandling af patienter med RCC blev der rapporteret hændelser med hjertesvigt (herunder hjertesvigt, kongestivt hjertesvigt, kardiopulmonalt svigt, venstre ventrikeldysfunktion, nedsat uddrivningsfraktion og højre ventrikelsvigt) (se pkt.
In clinical studies with axitinib for the treatment of patients with RCC, cardiac failure events (including cardiac failure, cardiac failure congestive, cardiopulmonary failure, left ventricular dysfunction, ejection fraction decreased, and right ventricular failure) were reported (see section
Inlyta indeholder lactose
Inlyta contains lactose (milk sugar)
Venøse tromboemboliske hændelser c, d, i
Venous embolic and thrombotic eventsc,d,i
Stigning i lipase Stigning i alaninaminotransferase Stigning i amylase Stigning i aspartataminotransferase Stigning i basisk fosfatase Stigning i kreatinin Stigning i TSH
Amylase increased Aspartate aminotransferase increased
I studier med axitinib givet som monoterapi (N = 672) til behandling af patienter med RCC blev der rapporteret hændelser med hjertesvigt (herunder hjertesvigt, kongestivt hjertesvigt, kardiopulmonalt svigt, venstre ventrikeldysfunktion, nedsat uddrivningsfraktion og højre ventrikelsvigt) hos 1,8 % af patienterne, der fik axitinib.
In monotherapy studies with axitinib (N = 672) for the treatment of patients with RCC, cardiac failure events (including cardiac failure, cardiac failure congestive, cardiopulmonary failure, left ventricular dysfunction, ejection fraction decreased, and right ventricular failure) were reported in 1.8% patients receiving axitinib.
Det skal du vide, før du begynder at tage Inlyta
What you need to know before you take Inlyta Do not take Inlyta:
Axitinib bør anvendes med forsigtighed hos patienter med risiko for eller som tidligere har haft en arteriel tromboembolisk hændelse.
Axitinib should be used with caution in patients who are at risk for, or who have a history of, these events.
I kliniske studier med axitinib til behandling af patienter med RCC, blev der set tilfælde af hypotyreose, og i mindre udstrækning hypertyreose (se pkt.
In clinical studies with axitinib for the treatment of patients with RCC, events of hypothyroidism and, to a lesser extent, hyperthyroidism, were reported (see section 4.8).
4.4 og 5.2).
29.4 (24.5, NE)
Posteriort reversibelt encefalopati-syndrom (PRES) Der er set PRES i kliniske studier (se pkt.
Posterior reversible encephalopathy syndrome (PRES) In clinical studies with axitinib, events of PRES were reported (see section 4.8).
Øvre abdominale smerter Flatulens
Abdominal pain Constipation
Sikkerhed og virkning af dette lægemiddel til børn og unge er ikke klarlagt.
This medicine has not been studied in children and adolescents.
• Fald i antal røde blodlegemer (ses i blodprøver)
• Reduction in the number of red blood cells (may show in your blood tests)
Dødelig lungeemboli blev set hos 1 patient (0,3%) i behandling med axitinib.
Fatal pulmonary embolism was reported in one patient (0.3%) receiving axitinib.
I et kontrolleret klinisk studie med axitinib som behandling af patienter med RCC er der set leverrelaterede bivirkninger.
In a controlled clinical study with axitinib for the treatment of patients with RCC, liver-related adverse reactions were reported.
Men samtidig administration af axitinib forventes ikke at hæmme P-glykoprotein ved terapeutiske plasmakoncentrationer, og det forventes derfor ikke, at samtidig administration af axitinib vil medføre en stigning i plasmakoncentrationen af digoxin eller andre P-glykoproteinsubstrater in vivo.
Therefore, co-administration of axitinib is not expected to increase the plasma concentration of digoxin, or other P-glycoprotein substrates,
Forlængelsen af den mediane progressionfri overlevelse var forskellig i de to undergrupper afhængigt af den tidligere behandling.
The magnitude of median PFS effect was different in the subgroups by prior therapy.
Ring straks til lægen ved symptomer som smerter eller trykken for brystet, smerter i armene, ryggen, nakken eller kæben, åndenød, følelsesløshed eller svaghed i den ene side af kroppen, problemer med at gå, hovedpine, synsforstyrrelser eller svimmelhed.
Get emergency help right away and call your doctor if you get symptoms such as chest pain or pressure; pain in your arms, back, neck or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; headache; vision changes: or dizziness.
• Forhøjet antal røde blodlegemer (ses i blodprøver)
• Increase in the number of red blood cells (may show in your blood tests)
Din læge vil jævnligt undersøge Dem for symptomer på hjertesvigt under behandlingen med axitinib.
Your doctor should monitor for signs or symptoms of heart failure events periodically throughout treatment with axitinib.
4.4: hjertesvigt, hypertension, thyroideadysfunktion, arterielle tromboemboliske hændelser, venøse tromboemboliske hændelser, stigning i hæmoglobin eller hæmatokrit, blødning, gastrointestinal perforation og fisteldannelse, komplikationer ved sårheling, PRES, proteinuri og stigning i leverenzymer.
The following risks, including appropriate action to be taken, are discussed in greater detail in section 4.4: cardiac failure events, hypertension, thyroid dysfunction, arterial thromboembolic events, venous thromboembolic events, elevation of haemoglobin or haematocrit, haemorrhage, gastrointestinal perforation and fistula formation, wound healing complications, PRES, proteinuria, and elevation of liver enzymes.
• Diarré, kvalme, opkastning, mavesmerter, fordøjelsesproblemer, øm mund, tunge og svælg,
• Diarrhoea, feeling or being sick (nausea or vomiting), stomach ache, indigestion, soreness of the mouth, tongue or throat, constipation
• Næseblod
• Nose bleeding
I studier med axitinib givet som monoterapi (N = 850) så man arterielle tromboemboliske bivirkninger (herunder transitoriske iskæmisk anfald, myokardieinfarkt og cerebrovaskulære hændelser) hos 5,3% af patienterne.
In monotherapy studies with axitinib (N = 850), arterial embolic and thrombotic adverse reactions (including transient ischemic attack, myocardial infarction, and cerebrovascular accident) were reported in 5.3% of patients receiving axitinib.
Gastrointestinal perforation og fistler inkluderer følgende termer: abdominal absces, anal absces, anal fistel, fistel, gastrointestinal anastomose lækage, gastrointestinal perforation, tyktarmsperforation, øsofagobronkial fistel og peritonitis Proteinuri inkluderer følgende termer: protein i urinen, protein til stede i urinen og proteinuri Inklusive akut nyresvigt n Cholecystitis inkluderer akut cholecystitis, cholecystitis, infektiøs cholecystitis
k Gastrointestinal perforation and fistula includes the following preferred terms: abdominal abscess, anal abscess, anal fistula, fistula, gastrointestinal anastomotic leak, gastrointestinal perforation, large intestine perforation, oesophagobronchial fistula and peritonitis.
Meget almindelig Hypertension Blødning c, d, h
Vascular disorders Very common Hypertensiong Haemorrhagec,d,h
I et kontrolleret klinisk studie med axitinib (N = 359) til behandling af patienter med RCC blev der rapporteret tilfælde af hjertesvigt hos 1,7 % af patienterne, der fik axitinib, herunder hjertesvigt (0,6 %), kardiopulmonalt svigt (0,6%), venstre ventrikeldysfunktion (0,3 %) og højre ventrikelsvigt (0,3 %).
In a controlled clinical study with axitinib (N = 359) for the treatment of patients with RCC, cardiac failure events were reported in 1.7 % patients receiving axitinib, including cardiac failure (0.6%), cardiopulmonary failure (0.6%), left ventricular dysfunction (0.3%), and right ventricular failure
IS
i
Pfizer Ελλάς A.E. Τλ: +30 210 6785 800
Τηλ: +30 210 6785 800
I et klinisk studie med axitinib til behandling af patienter med RCC, hvor patienter med ubehandlede hjernemetastaser var blevet ekskluderet, blev der rapporteret blødningsrelaterede bivirkninger hos 21,4% af patienterne i behandling med axitinib.
In a controlled clinical study with axitinib for the treatment of patients with RCC that excluded patients with untreated brain metastasis, haemorrhagic adverse reactions were reported in 21.4% of patients receiving axitinib.
Axitinib er ikke undersøgt hos patienter med nedsat nyrefunktion.
Axitinib has not been studied in subjects with renal impairment.
Ved mistanke om overdoseringer bør behandlingen ophøre og understøttende behandling iværksættes.
In cases of suspected overdose, axitinib should be withheld and supportive care instituted.
180 tabletter
PHARMACEUTICAL FORM AND CONTENTS 180 tablets
I fire kliniske studier med axitinib til behandling af patienter med RCC (N = 537) så man hæmoglobinniveauer over det normale hos 13,6% af patienterne i behandling med axitinib.
In four clinical studies with axitinib for the treatment of patients with RCC (N = 537), elevated haemoglobin above ULN was observed in 13.6% receiving axitinib.
Arterielle tromboemboliske hændelser (se pkt.
Arterial embolic and thrombotic events (see section 4.4)
Thyroideadysfunktion (se pkt.
Thyroid dysfunction (see section 4.4)
Patienter med serumkreatinin >1,5 gange den øvre normal grænse eller beregnet kreatininclearance <60 ml/min blev ekskluderet fra de kliniske studier.
In clinical studies with axitinib for the treatment of patients with RCC, patients with serum creatinine > 1.5 times the ULN or calculated creatinine clearance < 60 mL/min were excluded.
Inlyta 1 mg fås i beholdere med 180 tabletter og i blisterpakninger med 14 tabletter.
Inlyta 1 mg is available in bottles of 180 tablets and blisters of 14 tablets.
Blødningsrelaterede bivirkninger grad ≥3 blev set hos 3,1% af patienterne i behandling med axitinib (herunder hjerneblødning, gastrisk blødning, nedre gastrointestinal blødning og hæmoptyse).
Grade > 3 haemorrhagic adverse reactions were reported in 3.1% of patients receiving axitinib (including cerebral haemorrhage, gastric haemorrhage, lower gastrointestinal haemorrhage and haemoptysis).
Proteinuri Der er rapporteret proteinuri, herunder grad 3- og 4-proteinuri, i kliniske studier med axitinib (se pkt.
In clinical studies with axitinib, proteinuria, including that of Grade 3 and 4 severity, was reported (see section 4.8).
4.4) I et klinisk studie med axitinib til behandling af patienter med RCC, blev der rapporteret arterielle tromboemboliske bivirkninger hos 4,7% af de patienter,der fik axitinib, herunder myokardieinfarkt (1,4%), transitorisk cerebral iskæmi (0,8%) og cerebrovaskulære hændelser (0,6%).
In a controlled clinical study with axitinib for the treatment of patients with RCC, arterial embolic and thrombotic adverse reactions were reported in 4.7% of patients receiving axitinib, including myocardial infarction (1.4%), transient ischemic attack (0.8%) and cerebrovascular accident (0.6%).
Axitinib er ikke undersøgt hos patienter med svært nedsat leverfunktion (Child-Pugh klasse C) og bør ikke anvendes til denne gruppe patienter.
Axitinib has not been studied in patients with severe hepatic impairment (Child-Pugh class C) and should not be used in this population.
• Opsvulmet mave, hævede ben eller ankler, fremstående blodårer på halsen, usædvanlig træthed,
• Swelling of the abdomen, legs, or ankles, protruding neck veins, excessive tiredness,
Meget almindelig Artralgi Ekstremitetssmerter
Very common Arthralgia Pain in extremity
Dødelig blødning sås hos 1 patient (0,3%) i behandling med axitinib (gastrisk blødning).
Fatal haemorrhage was reported in one patient (0.3%) receiving axitinib (gastric haemorrhage).
• Hvis du får symptomer såsom usædvanlig træthed, opsvulmet mave, hævede ben eller ankler, åndenød eller fremstående blodårer på halsen under behandling med Inlyta.
• If during treatment with this medicine, you get symptoms such as excessive tiredness, swelling of the abdomen, legs or ankles, shortness of breath, or protruding neck veins.
Inlyta kan give problemer med skjoldbruskkirtlen.
Inlyta can cause thyroid gland problems.
HR (95% CI)
Median OS d in months (95% CI)
Der er set venøse tromboemboliske hændelser (herunder lungeemboli, dyb venetrombose og retinal vene okklusion/trombose) i kliniske studier med axitinib (se pkt.
In clinical studies with axitinib, venous embolic and thrombotic events (including pulmonary embolism, deep vein thrombosis, and retinal vein occlusion/thrombosis) were reported (see section 4.8).
Venøse tromboemboliske hændelser (se pkt.
Venous embolic and thrombotic events (see section 4.4)
4.4) I et klinisk studie med axitinib til behandling af patienter med RCC, blev der rapporteret venøse tromboemboliske hændelser hos 3,9% af patienterne, herunder lungeemboli (2,2%), retinalveneokklusion (trombose) (0,6%) og dyb venetrombose (0,6%).
In a controlled clinical study with axitinib for the treatment of patients with RCC, venous embolic and thrombotic adverse reactions were reported in 3.9% of patients receiving axitinib, including pulmonary embolism (2.2%), retinal vein occlusion/thrombosis (0.6%) and deep vein thrombosis (0.6%).
Hypertyreose
Hyperthyroidismc
• Hjertesvigt.
• Heart failure events.
Behandling med axitinib kan medføre stigning i hæmoglobin eller hæmatokrit, som tegn på en øget mængde røde blodlegemer (se pkt.
Increases in haemoglobin or haematocrit, reflective of increases in red blood cell mass, may occur during treatment with axitinib (see section 4.8, polycythaemia).
Samtidig anvendelse af potente CYP3A4/5-induktorer Samtidig anvendelse af axitinib og potente CYP3A4/5-induktorer kan nedsætte plasmakoncentrationen af axitinib (se pkt.
Co-administration of axitinib with strong CYP3A4/5 inducers may decrease axitinib plasma concentrations (see section 4.5).
Leverfunktionen skal kontrolleres før initiering af behandlingen og regelmæssigt under hele behandlingen med axitinib.
Liver function tests should be monitored before initiation of, and periodically throughout, treatment with axitinib.
Behandlingen med axitinib skal afbrydes midlertidigt eller permanent hos patienter med symptomer på PRES. Sikkerheden ved genoptagelse af behandlingen hos patienter, som har haft PRES, kendes ikke.
The safety of reinitiating axitinib therapy in patients previously experiencing PRES is not known.
Samtidig anvendelse af potente CYP3A4/5-hæmmere Samtidig anvendelse af axitinib og potente CYP3A4/5-hæmmere kan øge plasmakoncentrationen af axitinib (se pkt.
Co-administration of axitinib with strong CYP3A4/5 inhibitors may increase axitinib plasma concentrations (see section 4.5).
Dødeligt hjertesvigt blev rapporteret hos 0,6 % af patienterne, der fik axitinib.
Fatal cardiac failure was reported in 0.6 % of patients receiving axitinib.
Tel: +44 (0)1304 616161
United Kingdom Pfizer Limited Tel: +44 (0) 1304 616161
Mave-tarm-kanalen Meget almindelig Diarré Opkastning
Very common Diarrhoea Vomiting
Grad 4 hjertesvigt blev rapporteret hos 0,6 % af patienterne, der fik axitinib.
Grade 4 cardiac failure adverse reactions were reported in 0.6 % of patients receiving axitinib.
Grad 3/4 venøse tromboemboliske hændelse blev rapporteret hos 3,1% af patienterne i behandling med axitinib.
Grade 3/4 venous embolic and thrombotic adverse reactions were reported in 3.1% of patients receiving axitinib.
Meget almindelig Dyspnø Hoste
Very common Dyspnoead Cough
Inlyta 5 mg: hver tablet indeholder 5 mg axitinib
Inlyta 5 mg: each tablet contains 5 mg axitinib
Inlyta 7 mg: hver tablet indeholder 7 mg axitinib
Inlyta 7 mg: each tablet contains 7 mg axitinib
Inlyta 5 mg filmovertrukne tabletter Hver filmovertrukken tablet indeholder 5 mg axitinib.
Inlyta 5 mg film-coated tablets Each film-coated tablet contains 5 mg of axitinib.
Inlyta 7 mg filmovertrukne tabletter Hver filmovertrukken tablet indeholder 7 mg axitinib.
Inlyta 7 mg film-coated tablets Each film-coated tablet contains 7 mg of axitinib.
Grad 3/4 hjertesvigt blev rapporteret hos 1,0 % af patienterne, og dødeligt hjertesvigt blev rapporteret hos 0,3 % af patienterne, der fik axitinib.
Grade 3/4 cardiac failure events were reported in 1.0% patients and fatal cardiac failure events were reported in 0.3% patients receiving axitinib.
Pfizer Luxembourg SARL Pfizer.
Pfizer Luxembourg SARL, organizačná zložka
Inlyta 1 mg: hver tablet indeholder 1 mg axitinib
Inlyta 1 mg: each tablet contains 1 mg axitinib
Der bør dog udvises forsigtighed ved bilkørsel eller betjening af maskiner, hvis patienten oplever svimmelhed eller træthed under behandling med axitinib.
Patients should be advised that they may experience events such as dizziness and/or fatigue during treatment with axitinib.
Axitinib er ikke undersøgt hos patienter med alvorligt nedsat leverfunktion (Child-Pugh class C) og bør ikke anvendes til denne gruppe patienter (se pkt.
Axitinib has not been studied in patients with severe hepatic impairment (Child-Pugh class C) and should not be used in this population (see sections 4.4 and 5.2).
Inlyta 7 mg filmovertrukne tabletter er røde, diamantformede, præget med “Pfizer” på den ene side og “7 XNB” på den anden.
Inlyta 7 mg film-coated tablets are red, diamond shaped and debossed with “Pfizer” on one side and “7 XNB” on the other.
Inlyta 5 mg filmovertrukken tablet Hver filmovertrukken tablet indeholder 58,8 mg lactosemonohydrat.
Each film-coated tablet contains 58.8 mg of lactose monohydrate.
Inlyta 1 mg filmovertrukken tablet
Inlyta 1 mg film-coated tablet
• Rødmen og opsvulmning af håndflader og fodsåler (hånd- og fodsyndrom), hududslæt, tør hud
• Redness and swelling of the palms of the hands or soles of the feet (hand-foot syndrome),
Der skal observeres for bestemte hændelser, som beskrevet herunder, før behandlingsstart og regelmæssigt under behandlingen med axitinib.
Specific safety events should be monitored before initiation of, and periodically throughout, treatment with axitinib as described below.
Inlyta 3 mg filmovertrukne tabletter Hver filmovertrukken tablet indeholder 3 mg axitinib.
Inlyta 3 mg film-coated tablets Each film-coated tablet contains 3 mg of axitinib.
I poolede kliniske studier med axitinib (N = 672) til behandling af RCC blev der rapporteret gastrointestinal perforation og fistler hos 1,9% af de patienter, der fik axitinib.
In pooled clinical studies with axitinib (N = 672) for the treatment of patients with RCC, gastrointestinal perforation and fistula were reported in 1.9% of patients receiving axitinib.
Inlyta 5 mg fås i beholdere med 60 tabletter og i blisterpakninger med 14 tabletter.
Inlyta 5 mg is available in bottles of 60 tablets and blisters of 14 tablets.
Orofaryngeal smerte
Oropharyngeal pain
Inlyta 3 mg: hver tablet indeholder 3 mg axitinib
Inlyta 3 mg: each tablet contains 3 mg axitinib
Inlyta 7 mg fås i beholdere med 60 tabletter og i blisterpakninger med 14 tabletter.
Inlyta 7 mg is available in bottles of 60 tablets and blisters of 14 tablets.
EU/1/12/777/010 28 tabletter EU/1/12/777/011 56 tabletter
EU/1/12/777/011 56 tablets
Inlyta 7 mg filmovertrukken tablet
Inlyta 7 mg film-coated tablet
Inlyta 7 mg filmovertrukne tabletter EU/1/12/777/010
Inlyta 7 mg film-coated tablets EU/1/12/777/010
Rød rombeformet filmovertrukken tablet præget med ”Pfizer” på den ene side og ”7 XNB” på den anden.
Red diamond shaped film-coated tablet debossed with “Pfizer” on one side and “7 XNB” on the other.
Inlyta 1 mg filmovertrukne tabletter er røde, ovale, præget med “Pfizer” på den ene side og “1 XNB” på den anden.
Inlyta 1 mg film-coated tablets are red, oval and debossed with “Pfizer” on one side and “1 XNB” on the other.
Inlyta 5 mg filmovertrukne tabletter er røde, trekantede, præget med “Pfizer” på den ene side og “5 XNB” på den anden.
Inlyta 5 mg film-coated tablets are red, triangular and debossed with “Pfizer” on one side and “5 XNB” on the other.